Leadership & Pay ·
Bausch + Lomb Corporation appointed four new directors—Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and…
BLCOBausch & Lomb Corp
Bausch + Lomb Corporation appointed four new directors—Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi—to its board effective August 5, 2026, replacing Steven H. Collis, Karen L. Ling, Thomas W. Ross, Sr., and Andrew C. von Eschenbach, M.D. The new appointments were made at the request of controlling shareholder Bausch Health Companies Inc. Resigning directors received prorated compensation and accelerated vesting of unvested restricted stock units; Mr. Ross entered a one-year consulting agreement with a $400,000 fee. The company reported second-quarter revenue of $1.394 billion, an 8% increase on a constant currency basis, and reaffirmed full-year 2026 guidance for revenue between $5.440 billion and $5.540 billion. Bausch + Lomb Corporation is a global eye health company that manufactures contact lenses, surgical devices, and pharmaceutical products.